A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy
Launched by CHANGHAI HOSPITAL · Nov 22, 2024
Trial Information
Current as of June 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how effective urgent angioplasty (a procedure to open blocked blood vessels) is for patients who have had a stroke caused by narrowing of the arteries in the brain, specifically after they have already undergone a procedure called mechanical thrombectomy to remove a blood clot. The goal is to see if this additional step improves recovery and outcomes for patients who have experienced a type of stroke known as acute ischemic stroke.
To participate in this trial, individuals need to be at least 18 years old and have a certain level of stroke severity before being treated. They must receive the thrombectomy within 24 hours after the stroke starts and have specific imaging results that indicate they might benefit from angioplasty. The trial is not currently recruiting participants, and those who join will be closely monitored for their health outcomes after the procedures. It’s important to note that there are several criteria that might exclude someone from joining, such as having certain types of bleeding or other serious health issues. Overall, this trial aims to provide valuable information that could help improve treatment options for stroke patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Clinical inclusion criteria:
- • 1. Age ≥ 18 years
- • 2. National Institutes of Health Stroke Scale (NIHSS) score ≥6 before randomization
- • 3. To receive mechanical thrombectomy \<24 hours after AIS onset according to local guidelines
- • 4. Signed informed consent form obtained from the subject (or approved surrogate)
- Imaging inclusion criteria:
- • 1. For subjects with anterior circulation stroke, ASPECTS ≥6 based on CT or DWI
- • 2. For subjects with posterior circulation stroke, posterior circulation ASPECTS (pc-ASPECTS)≥6 and pons-midbrains index (PMI) \< 3 based on CT or DWI
- Angiography inclusion criteria:
- • 1. The responsible occluded vessel is immediately recanalized (eTICI≥2b) after mechanical thrombectomy, ICAS is highly suspected and the focal residual stenosis of the main trunk is≥70%, and the responsible occluded vessels include the intracranial segment of the internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, and the basilar artery
- • 2. According to the judgment of the neurointerventional physician, the responsible artery is suitable for stenting angioplasty
- Exclusion Criteria:
- • 1. Pre-stroke mRS \>2
- • 2. Intracranial hemorrhage confirmed by CT before mechanical thrombectomy and enrolment
- • 3. Suspected Intracranial hemorrhage after successful recanalization confirmed by 3D-CT
- • 4. Tandem lesions: stenosis (or occlusion) of the extracranial segment of the internal carotid artery or vertebral artery combined with occlusion of large intracranial vessels, stenosis of intracranial arteries combined with occlusion of vessels distal to the stenosis
- • 5. More than two severe stenosis of the responsible occluded vessel (internal carotid artery, middle cerebral artery, vertebral artery, and basilar artery)
- • 6. Potential cardiac sources of emboli such as atrial fibrillation, left ventricular thrombus, heart valve replacement, atrial septal defect, ventricular septal defect, atrial myxoma, etc.
- • 7. Current use of oral anticoagulants
- • 8. Major surgery or serious trauma in the previous 2 weeks
- • 9. Contraindication for mechanical thrombectomy or stenting angioplasty
- • 10. Contraindication for antiplatelet treatment or allergy to contrast agent
- • 11. History of gastrointestinal or urinary bleeding in the previous 3 weeks
- • 12. Life expectancy less than 1 years
- • 13. Current pregnant or breastfeeding status
- • 14. Currently participating in another clinical trial that may affect the outcome assessment of this trial
- • 15. Any other condition that, in the investigator's judgement, deems the individual unsuitable for enrolment.
About Changhai Hospital
Changhai Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence, the hospital integrates cutting-edge medical technologies and a multidisciplinary approach to patient care. Changhai Hospital actively collaborates with research organizations and healthcare professionals to conduct rigorous clinical trials aimed at developing new treatments and improving patient outcomes. By prioritizing patient safety and ethical standards, the hospital plays a pivotal role in contributing to the advancement of medical knowledge and the enhancement of therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jianmin Liu, MD, PhD
Principal Investigator
Changhai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported